Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 14/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.53 |
| ▸ | GHSR | Q92847 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7804318 | 0.91 | MAP2K4 (0.53) | ACLYALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL23229428 | 0.85 | ALDH1A1 (0.64) | ALDH1A1KDM4ELMNAMAPTHPGD | |
| SCHEMBL7803384 | 0.83 | HPGD (0.69) | ACLYALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL8280437 | 0.80 | LMNA (0.63) | ACLYALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL7804642 | 0.79 | KMT2A (0.70) | ACLYALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL4183800 | 0.78 | KEAP1 (0.56) | KMT2AMAP2K4 | |
| SCHEMBL8281106 | 0.78 | PFKFB3 (0.54) | ACLYALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL11956218 | 0.77 | PIK3CA (0.43) | ACLYALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL25072952 | 0.77 | ACLY (0.67) | ACLYALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL3335969 | 0.76 | MEN1 (0.65) | ALDH1A1KDM4ELMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | ACLY 3142/4885ALDH1A1 838/4885KDM4E 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.